R&D channel feed – Endpoints News

R&D channel feed

#ASH17: Roche unveils stellar PhII DLBCL data for one of its top hematology drugs in the pipeline

8 years ago

#ASH17: Seattle Genetics CEO Clay Siegall has an answer for the skeptics doubting Adcetris data for Hodgkin lymphoma

8 years ago

In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib

8 years ago

Sage triggers another burst of investor enthusiasm as oral depression drug scores in PhII

8 years ago

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

8 years ago

There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?

8 years ago

Looking for a come-from-behind win, Roche touts its pivotal success for Tecentriq combo in front-line lung cancer

8 years ago

More efficient rare pediatric drug development: FDA drafts guidance

8 years ago

Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA

8 years ago

Madrigal's stock soars on promising PhII data in NASH, but questions linger

8 years ago

Cancer R&D tips the scales at the FDA as active INDs climb to record high

8 years ago

Galectin PhIIb NASH trial fails the primary goal, but researchers hammer on the positive

8 years ago

Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials

8 years ago

Ra Pharma puts its best foot forward with PhII Soliris rival, but shares crash after comparison to Alexion’s next-gen drug

8 years ago

Ultragenyx shares surge as blockbuster hopeful burosumab continues to perform in pivotal study

8 years ago

Sanofi’s belated admission of a lethal Dengvaxia threat came long after multiple high-profile warnings

8 years ago

Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure

8 years ago

Researchers use PD-1 checkpoint drug in pursuit of a promising curative approach to HIV

8 years ago

Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early

8 years ago

Shire CEO Ornskov woos Bayer’s Andreas Busch to run Boston-based R&D group

8 years ago

What's killing patients in Bayer's Xofigo combo study? Researchers unblind study early to probe safety alert

8 years ago

In reorganization, Joerg Moeller gathers all the pharma R&D reins at Bayer as discovery chief exits

8 years ago

Sanofi’s dengue vaccine slams into a safety issue, triggering a $120M write-off and eviscerating old blockbuster projections

8 years ago

J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine

8 years ago

First page Previous page 284 285 286287288 289 290 Next page Last page